Last updated: August 28, 2023
Sponsor: National University of Malaysia
Overall Status: Active - Recruiting
Phase
N/A
Condition
Allergy
Allergies & Asthma
Common Cold
Treatment
Placebo
Ascorbic acid 1000mg
Clinical Study ID
NCT05810233
JEP-2023
Ages 18-40 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Participants above 18-years old
- Participants with history at least 2 symptoms of rhinitis triggered by dust
- Positive SPT to Dermatophagoides pteronyssinus with wheal reaction of at least 5 mmdone within the past 1 year.
Exclusion
Exclusion Criteria:
- Prior skin prick test result form do not include a tracing of the wheal reaction.
- Prior skin prick test was not performed in HCTM.
- Participants who are actively smoking or who have smoked cigarette or vaped in thepast 6 months
- Participants with skin conditions affecting the volar aspects of the arm.
- Participants on beta-blockers
- Participants contraindicated for skin prick test (pregnancy, history of anaphylaxis,poorly controlled asthma)
- Participants on long term supplements (multivitamin, traditional supplement)
- Participants contraindicated for vitamin c (vitamin c allergy, kidney dysfunction,history of kidney or bladder stones, hyperuricemia, thalassemia, G6PD deficiency,sickle cell disease, hamatochromatosis)
- Participants at risk of vitamin C deficiency (hyperthyroidism, elderly, beastfeeding,diarrhoea, restricted diet secondary to inflammatory bowel disease, anorexia orcancer)
Study Design
Total Participants: 90
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
July 15, 2023
Estimated Completion Date:
January 30, 2024
Study Description
Connect with a study center
Hospital Canselor Tuanku Mukhriz
Cheras, WP Kuala Lumpur 56000
MalaysiaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.